Entries by SM

$INSM gets wide coverage

Stifel Nicolaus Reiterates Buy target raised $27.00 -> $43.00 Robert W. Baird Reiterates Outperform -> Positive raising target $23.00 -> $32.00 Cowen and Company Reiterates Outperform with target $54.00 HC Wainwright Reiterates Buy with target $35.00 Evercore ISI Raises Target from $28.00 -> $40.00 with Outperform rating Leerink Swann Raises Target 1$27.00 -> $36.00 with […]

Target raised on $HALO

Deutsche Bank AG Raises Target on Halozyme Therapeutics (HALO) to $20 with Buy rating. BMO Capital Markets Raises Target from $14.00 -> $15.00 with Market Perform rating. Check our detailed coverage on HALO at our SeekingAlpha Marketplace page.

$BMY gets varied coverage

BMO Capital Markets Reiterates Sell on BMY at $49.00. Credit Suisse Group Reiterates Neutral -> Hold. Goldman Sachs Reiterates Buy with target $62.00 -> $65.00. Get in-depth analysis in our Daily Pharma Scoop at SeekingAlpha Marketplace.

J P Morgan upgrades $BCRX

J P Morgan Chase & Co Upgrades BioCryst Pharmaceuticals (BCRX) from Neutral to Overweight with target raised from $6 to $9. Check out more ratings on our SeekingAlpha Marketplace Daily Pharma Scoop.

Target raised on $AVDL

Langenberg & Company Reiterates Buy target $27.00 -> $30.00 Ladenburg Thalmann Raises Target $27.00 -> $30.00 Check out more ratings on our SeekingAlpha Marketplace page.

$ALNY covered widely

Instinet reduces target to $56.00 Leerink Swann Reiterates Market Perform with target $83.00 -> $72.00 Needham & Company Reiterates Buy - $98.00 -> $85.00 Barclays Reiterates Equal Weight -> Overweight with target $80.00 -> $105.00 Piper Jaffray Reiterates Overweight at $126.00 -> $110.00 Check out more ratings on our SeekingAlpha Marketplace page.

Why did $LXRX suddenly go down last week?

Analysis of top Seeking Alpha coverage: Last Thursday, there was one important Editor’s Pick article on Lexicon Pharma (LXRX), one of our watchlist stocks. We analyse it in today's pharma scoop.  The full unabridged post can be accessed on our SeekingAlpha Marketplace page.

Daily pharma scoop: $ACAD growth potential

ACADIA (ACAD) is a company that has a single drug in its pipeline - pimavanserin, brand name Nuplazid. Nuplazid was approved in March for treating Parkinson’s Disease Psychosis or PDP, which are symptomatic delusions and hallucinations associated with Parkinson’s Disease. The full unabridged post can be accessed on our SeekingAlpha Marketplace page.